Advertisement

Advertisement
Multiple Myeloma

FDA Approves Biweekly Teclistamab Dosing Regimen for Patients With Multiple Myeloma

On February 20, the U.S. Food and Drug Administration (FDA) approved the supplemental biologics license application for teclistamab-cqyv (Tecvayli) for a reduced...

Colorectal Cancer

Multitarget Fecal Immunochemical Test in Stool-Based Colorectal Cancer Screening

In a Dutch study reported in The Lancet Oncology, Wisse et al found that a multitarget fecal immunochemical test (mtFIT) improved detection of advanced adenomas vs standard...

Multiple Myeloma

Understanding Risk Stratification in Monoclonal Gammopathy of Undetermined Significance

About 4 years ago, I [Jo Cavallo] wrote about the death of my brother Dom from multiple myeloma in 2011 and my subsequent enrollment in the PROMISE trial...


Advertisement
Multiple Myeloma

DREAMM-7 Confirms Benefit of Triplet Regimen in Relapsed or Refractory Multiple Myeloma

Positive results were reported for belantamab mafodotin-blmf plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma...

Lung Cancer

Osimertinib vs Sequential Gefitinib/Osimertinib in Advanced EGFR-Mutant NSCLC

As reported in the Journal of Clinical Oncology by Jordi Remon, MD, PhD, and colleagues, the final analysis of overall survival in the phase II EORTC APPLE trial showed...

Advertisement
Advertisement





Lung Cancer
Issues in Oncology

Debora S. Bruno, MD, on NSCLC: Racial Disparities in Biomarker Testing and Clinical Trial Enrollment

Head and Neck Cancer
Immunotherapy

Toripalimab Plus Gemcitabine/Cisplatin Extends Progression-Free Survival in Recurrent or Metastatic Nasopharyngeal Carcinoma: JUPITER-02

According to the results from the phase III JUPITER-02 study, the addition of toripalimab, a humanized IgG4K anti–PD-1 monoclonal antibody, to standard gemcitabine/cisplatin chemotherapy as first-line treatment for patients with advanced nasopharyngeal carcinoma provided superior progression-free...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Skin Cancer

Jessica C. Hassel, MD, on Uveal Melanoma: Comparing Tebentafusp With Standard Therapies

Bladder Cancer
Immunotherapy

KEYNOTE-361: First-Line Pembrolizumab With or Without Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Carcinoma

As reported in The Lancet Oncology by Thomas Powles, MD, PhD, and colleagues, the phase III KEYNOTE-361 trial has shown no significant improvement in progression-free or overall survival with first-line pembrolizumab plus platinum-based chemotherapy vs chemotherapy alone in patients with advanced...

Kidney Cancer
Immunotherapy

Adjuvant Pembrolizumab Extends Disease-Free Survival in High-Risk Renal Cell Carcinoma

Immunotherapy following surgery significantly improved disease-free survival compared to placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to results from the international phase III KEYNOTE-564 study presented at the 2021 ASCO Annual Meeting by Toni K....

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Breast Cancer

Geoffrey J. Lindeman, MBBS, PhD, on Breast Cancer: Venetoclax and Fulvestrant in ER-Positive, HER2-Negative Disease

Colorectal Cancer
Global Cancer Care

Colorectal Cancer Incidence and Mortality in European Countries

In a European population-based study reported in The Lancet Oncology, Cardoso et al found that colorectal cancer incidence and mortality declined more in European countries with long-standing colonoscopy or fecal test screening programs since the year 2000 compared to countries with more recently...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...

Twitter